Study of PRIM-DJ2727 for Ulcerative Colitis in Remission
This study is looking at the safety and effectiveness of an oral capsule called PRIM-DJ2727 for adults with ulcerative colitis (UC) who are currently in remission. PRIM-DJ2727 is a Fecal Microbiota Transplantation (FMT) product, meaning it contains beneficial gut bacteria from screened donors. You could be eligible if you are an adult aged 18 or older with a history of active UC in the past year, are currently in remission, and are on stable maintenance therapy. The study aims to see if PRIM-DJ2727 can help prevent UC relapse or inflammation, with success measured by a partial Mayo score of 3 or less after 9 months. This study is currently recruiting about 58 participants.
- Study design
- This interventional study will compare PRIM-DJ2727 capsules to a placebo (a capsule without active ingredients) in approximately 58 participants. It is designed to evaluate the treatment's effects.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be evaluated for remission at 9 months after starting the PRIM-DJ2727 capsules.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Patients in remission after administering 12 weeks of PRIM-DJ2727 capsules will be measured by partial Mayo score ≤ 39 months